2nd Quarter - Report

ZIRKELBACH STRATEGIES for AMAG PHARMACEUTICALS

Firm
Client
Income
$45,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Pharmaceutical issues related to womens health product access and education on the accelerated approval pathway

LobbyistCovered position, as disclosed
MARY KATHLEEN ZIRKELBACH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.